No | Study Country | Study type | Study duration | Setting | Cohort size (n) | Patients with hCa (n) | Patients with shCa (n) | Definitions of hCa and shCa | Age– years, mean ±  SD | Male (%) | Blunt injury (%) | ISS, median (IQR) | Mortality (%) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
hCa | Normal Ca | hCa | Normal Ca | ||||||||||||
1 | Vivien, 2005 France | Prospective observational cohort | 2002 | Level 1 academic trauma center | 212 | 156 | 21 | hCa: iCa < 1.15 mmol/L shCa: iCa < 0.9 mmol/L | 37 ± 16 | 74 | 98 | 34 (29–36)a 59 (41–75)b | 16 (12–24) | 19a, 71b | 5 |
2 | Cherry, 2006 USA | Retrospective observational cohort | 2000–2002 | Level 1 trauma center | 396 | 91 | N/A | iCa < 1 mmol/L | 37 ± 5 | N/A | N/A | 25 (13–34) | 22 (13–34) | 26 | 16 |
3 | Choi, 2008 Korea | Ambispective observational cohort | 2005 | University hospital | 255 | 248 | 53 | hCa: iCa < 1.15 mmol/L shCa: iCa < 0.88 mmol/L | 47 ± 16 | 77 | 95 | N/A | N/A | 11a, 30b | 14 |
4 | Magnotti, 2011 USA | Prospective observational cohort | 2008 | Level 1 trauma center | 591 | 332 | N/A | iCa < 1 mmol/L | 38c | 78 | 78 | 23 | 18 | 16 | 9 |
5 | Webster, 2016 UK | Retrospective observational cohort | 2013–2014 | Trauma audit research network | 55 | 30 | N/A | iCa < 1.1 mmol/L | 33c | 65 | 82 | N/A | N/A | N/A | N/A |
6 | Vasudeva, 2019 Australia | Retrospective observational cohort | 2014–2018 | Level 1 trauma center | 226 | 113 | 6 | hCa: iCa < 1.1 mmol/L shCa: iCa < 0.8 mmol/L | 44 ± 21 | 66 | 86 | 38 (24–43) | 26 (17–34) | 26 | 15 |
7 | Byerly, 2020 USA | Retrospective observational cohort | 2004 | Level 1 trauma center | 7,341 | N/A | 716 | shCa: iCa < 0.9 mmol/L | 39 (26–55)c | 81 | 51 | 25 (14–34)b | 14 (9–22) | 38b | 10 |
8 | Helshoot, 2023 Multi-center | Retrospective observational cohort | 2015–2019 | Trauma registry DGU | 30,183 | 3,982 | 240 | hCa: iCa < 1.1 mmol/L shCa: iCa < 0.9 mmol/L | 54 (35–70)c | 71 | 93 | 22 (16–29) | 20 (14–29) | 21a, 36b | 14 |
9 | Scahid Jr, 2023 USA | Prospective observational cohort | N/A | Urban level 1 trauma center | 68 | 16 | N/A | iCa < 1 mmol/L | 37 ± 18 | 81 | 81 | 22 (15–34) | 13 (8–24) | 12 | 8 |
10 | Badarni, 2023 Israel | Retrospective observational cohort | 2014–2020 | Level 1 trauma center | 201 | 147 | 13 | hCa: iCa < 1.16 mmol/L shCa: iCa < 1 mmol/L | 53 (28–69)c | 82 | 95 | 29 (25–30) | 26 (25–29) | 20 | 19 |
11 | Maekkodathil, 2023 Qatar | Retrospective observational cohort | 2016–2021 | Level 1 trauma center | 922 | 757 | N/A | Ca < 2.2 mmol/L | 32 ± 15 | 94 | N/A | 23 ± 11d | 28 ± 10d | 24 | 12 |
12 | Vettorello, 2023 Italy | Retrospective observational cohort | 2015–2021 | Level 1 trauma center | 798 | 129 | N/A | iCa < 1.11 mmol/L | 47 ± 20 | 74 | 100 | 38 (28–50) | 26 (20–33) | 13 | 3 |
13 | Ahmed, 2024 Egypt | Prospective observational cohort | 2022 | Level 1 trauma center | 60 | 30 | N/A | iCa < 1.11 mmol/L | 46 ± 18 | 87 | 100 | N/A | N/A | 73 | 30 |
14 | Ciaraglia, 2024 USA | Retrospective observational cohort | 2016–2019 | Trauma registry | 1,981 | 869 | N/A | iCa < 1 mmol/L | 40 (27–58)c | 73 | 73 | N/A | N/A | 16 | 11 |
15 | Liaud-Laval, 2024 France | Retrospective observational cohort | 2015–2021 | Level 1 trauma center | 137 | 134 | 23 | hCa: iCa < 1.2 mmol/L shCa: iCa < 0.9 mmol/L | 39 (23–55)c | 76 | 75 | 26 (17–34)a 34 (27–40)b | 26 (19–34) | 39b | N/A |